Our study showed that striatal DAT binding correlated with the CSF concentration of HVA, a major metabolite of dopamine, in both PD and PSP, and that striatal DAT binding in PSP was significantly lower than that in PD, adjusting for CSF HVA concentration. The gene discussed is SLC6A3; the disease is supranuclear palsy, progressive, 1.